Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6197
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLewis, Alexander Cen
dc.contributor.authorPope, Victoria Sen
dc.contributor.authorTea, Melinda Nen
dc.contributor.authorLi, Manjunen
dc.contributor.authorNwosu, Gus Oen
dc.contributor.authorNguyen, Thao Men
dc.contributor.authorWallington-Gates, Craigen
dc.contributor.authorMoretti, Paul A Ben
dc.contributor.authorAnderson, Dovileen
dc.contributor.authorCreek, Darren Jen
dc.contributor.authorCostabile, Maurizioen
dc.contributor.authorAli, Saira Ren
dc.contributor.authorThompson-Peach, Chloe A Len
dc.contributor.authorDredge, B Kateen
dc.contributor.authorBert, Andrew Gen
dc.contributor.authorGoodall, Gregory Jen
dc.contributor.authorEkert, Paul Gen
dc.contributor.authorBrown, Anna Len
dc.contributor.authorD'Andrea, Richarden
dc.contributor.authorRobinson, Nirmalen
dc.contributor.authorPitman, Melissa Ren
dc.contributor.authorThomas, Danielen
dc.contributor.authorRoss, David Men
dc.contributor.authorGliddon, Briony Len
dc.contributor.authorPowell, Jason Aen
dc.contributor.authorPitson, Stuart Men
dc.date.accessioned2024-08-08T03:23:37Z-
dc.date.available2024-08-08T03:23:37Z-
dc.date.issued2022-06-30-
dc.identifier.citationBlood, 2022en
dc.identifier.urihttps://dora.health.qld.gov.au/qldresearchjspui/handle/1/6197-
dc.description.abstractInducing cell death by the sphingolipid ceramide is a potential anticancer strategy, but the underlying mechanisms remain poorly defined. In this study, triggering an accumulation of ceramide in acute myeloid leukemia (AML) cells by inhibition of sphingosine kinase induced an apoptotic integrated stress response (ISR) through protein kinase R-mediated activation of the master transcription factor ATF4. This effect led to transcription of the BH3-only protein Noxa and degradation of the prosurvival Mcl-1 protein on which AML cells are highly dependent for survival. Targeting this novel ISR pathway, in combination with the Bcl-2 inhibitor venetoclax, synergistically killed primary AML blasts, including those with venetoclax-resistant mutations, as well as immunophenotypic leukemic stem cells, and reduced leukemic engraftment in patient-derived AML xenografts. Collectively, these findings provide mechanistic insight into the anticancer effects of ceramide and preclinical evidence for new approaches to augment Bcl-2 inhibition in the therapy of AML and other cancers with high Mcl-1 dependency.en
dc.language.isoenen
dc.publisherAmerican Society of Hematologyen
dc.titleCeramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemiaen
dc.typeArticleen
dc.identifier.doi10.1182/blood.2021013277-
dc.identifier.pmid35443029-
dc.rights.holderCraig Wallington-Gatesen
dc.identifier.journaltitleBlood-
dc.identifier.external111854919-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypeArticle-
Appears in Sites:Sunshine Coast HHS Publications
Show simple item record

Page view(s)

54
checked on Dec 21, 2024

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.